September 2012. Volume 8. Number 3

Xanthines are still the treatment of choice for apnea of prematurity

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Alvaro RE, Khalil M, Qurashi M, Al-Saif S, Al-Matary A, Chiu A, et al. CO2 Inhalation as a treatment for apnea of prematurity: a randomized double-blind controlled trial. J Pediatr. 2012;160:252-7.
Reviewers: Rivas Fernández MÁ1, Sánchez Bueno I2, Buñuel Álvarez JC3.
1Hospital General de Cataluña. Sant Cugat del Vallés. Barcelona. España.
2Hospital Universitario Dr. Josep Trueta. Girona. Girona. España.
3Àrea Bàsica de Salut Girona-4. Institut Català de la Salut. Girona. España.
Correspondence: Mª Ángeles Rivas Fernández. Email: mayrivas5@gmail.com
Reception date: 19/06/2012
Acceptance date: 20/06/2012
Publication date: 04/07/2012

Abstract

Authors’ conclusions: inhaled carbon dioxide (CO2) can not be considered as an alternative to oral theophylline for the treatment of apnea of prematurity.

Reviewers’ commentary: the decline intotal time of apnea was significantly higher in preterm infants treated with theophylline. The CO2 is not a therapeutic alternative to theophylline for the treatment of apnea of prematurity, so it should not be used.

How to cite this article

Rivas Fernández MA, Sánchez Bueno I, Buñuel Álvarez JC. Las xantinas siguen siendo el tratamiento de elección de la apnea de la prematuridad. Evid Pediatr. 2012;8:54.

AVC | Critically appraised articles

Alvaro RE, Khalil M, Qurashi M, Al-Saif S, Al-Matary A, Chiu A, et al. CO2 Inhalation as a treatment for apnea of prematurity: a randomized double-blind controlled trial. J Pediatr. 2012;160:252-7.
Reviewers: Rivas Fernández MÁ1, Sánchez Bueno I2, Buñuel Álvarez JC3.
1Hospital General de Cataluña. Sant Cugat del Vallés. Barcelona. España.
2Hospital Universitario Dr. Josep Trueta. Girona. Girona. España.
3Àrea Bàsica de Salut Girona-4. Institut Català de la Salut. Girona. España.
Correspondence: Mª Ángeles Rivas Fernández. Email: mayrivas5@gmail.com
Reception date: 19/06/2012
Acceptance date: 20/06/2012
Publication date: 04/07/2012

How to cite this article

Rivas Fernández MA, Sánchez Bueno I, Buñuel Álvarez JC. Las xantinas siguen siendo el tratamiento de elección de la apnea de la prematuridad. Evid Pediatr. 2012;8:54.

References

  1. Committee on fetus and newborn. American Academy of Pediatrics. Apnea, sudden infant death syndrome, and home monitoring. Pediatrics. 2003;111:914.
  2. Bernaola Aponte G, Aparicio Sánchez JL. En los recién nacidos afectos de apneas de la prematuridad, el tratamiento con cafeína parece tener un efecto beneficioso sobre el desarrollo neurológico a largo plazo. Evid Pediatr. 2008;4:4.   
  3. Henderson-Smart DJ, De Paoli AG. Prophylactic methylxanthine for prevention of apnoea in preterm infants. Cochrane Database Syst Rev. 2010;(12):CD000432.
  4. Schmidt B, Anderson PJ, Doyle LW, Dewey D, Grunau RE, Asztalos EV et al. Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. JAMA. 2012;307:275-82.
  5. González de Dios J, Balaguer Santamaría A. El tratamiento de la apnea de la prematuridad con cafeína parece eficaz para disminuir la incidencia de displasia broncopulmonar. Evid Pediatr. 2006;2:44.
  6. Al-Saif S, Alvaro R, Manfreda J, Kwiatkowski K, Cates D, Qurashi M et al. Randomized controlled trial of theophylline versus CO2 inhalation for treating apnea of prematurity. J Pediatr. 2008;153:513-8.
  7. Fabres J, Carlo WA, Phillips V, Howard G, Ambalavanan N. Both extremes of arterial carbon dioxide pressure and the magnitude of fluctuations in arterial carbon dioxide pressure are associated with severe intraventricular hemorrhage in preterm infants. Pediatrics. 2007;119:299.
04/07/2012

Linked Comment